{"id":"NCT04660539","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)","officialTitle":"A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-02","primaryCompletion":"2024-05-28","completion":"2024-05-28","firstPosted":"2020-12-09","resultsPosted":"2024-12-27","lastUpdate":"2024-12-27"},"enrollment":119,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neuromyelitis Optica Spectrum Disorder"],"interventions":[{"type":"DRUG","name":"satralizumab","otherNames":["Enspryng"]},{"type":"DRUG","name":"azathioprine (AZA)","otherNames":["non-investigational medicinal product (NIMP)"]},{"type":"DRUG","name":"mycophenolate mofetil (MMF)","otherNames":["NIMP"]},{"type":"DRUG","name":"oral corticosteroids","otherNames":["NIMP"]}],"arms":[{"label":"Satralizumab Treatment","type":"EXPERIMENTAL"}],"summary":"This multicenter, single-arm, open-label study will evaluate the long-term safety and efficacy of satralizumab in participants with neuromyelitis optica spectrum disorder (NMOSD) who completed open-label extension (OLE) period of studies BN40898 and BN40900. Participants will receive satralizumab as monotherapy or in combination with one of the following background immunosuppressive treatments: azathioprine (AZA), mycophenolate mofetil (MMF), or oral corticosteroids.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Baseline up to 523 weeks","effectByArm":[{"arm":"Satralizumab","deltaMin":162,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":53,"countries":["United States","Bulgaria","Canada","Croatia","Germany","Hungary","Italy","Japan","Malaysia","Poland","Puerto Rico","Romania","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["40743487"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":166},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Urinary tract infection","Arthralgia"]}}